Trial Profile
A Study to Evaluate the Prognostic Role of Thioredoxin Reductases 1 in Metastatic Non-Small-Cell Lung Cancer Harboring EGFR Sensitive Mutation Treated With 1st Line Erlotinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 20 Apr 2016 New trial record